|
시장보고서
상품코드
1873364
세계의 병리 검사 시장 : 시장 점유율과 순위, 전체 판매 및 수요 예측(2025-2031년)Pathological Examination - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 |
||||||
QYResearch
세계의 병리 검사 시장 규모는 2024년에 341억 3,300만 달러로 추정되며, 2025년부터 2031년까지 예측 기간 동안 CAGR 10.0%로 성장하여 2031년까지 659억 1,200만 달러로 확대될 것으로 예측됩니다.
병리검사는 조직, 세포, 체액을 분석하여 질병의 성질, 원인, 진행 정도를 판단하는 의료 진단 과정입니다. 조직병리학, 세포진단, 면역조직화학, 분자병리학 등의 기술이 포함됩니다. 병리검사는 암을 비롯한 많은 질병 진단의 표준으로 임상적 판단, 수술 계획, 예후 평가에 있어 매우 중요한 역할을 합니다.
병리 검사 시장은 조직 기반 진단이 필요한 암 및 기타 만성질환의 전 세계 발생률 증가에 힘입어 성장하고 있습니다. 의료시스템이 정밀의료로 전환되면서 조직병리, 세포진단, 분자병리 등 정확하고 초기 단계의 진단 도구에 대한 수요는 지속적으로 증가하고 있습니다. 디지털 병리학, 면역조직화학(IHC), 차세대염기서열분석(NGS) 등의 기술 발전으로 병리학의 영역은 기존의 현미경 검사를 넘어 워크플로우의 효율화, 진단 정확도 향상, 개인별 맞춤 치료 전략의 실현이 가능해졌습니다.
높은 성장 잠재력에도 불구하고 병리검사 시장은 특히 개발도상국에서 숙련된 병리학자 부족과 같은 주요 과제에 직면해 있습니다. 기존 병리 검사의 수작업 워크플로는 시간이 오래 걸리고 오류가 발생하기 쉬운 경향이 있습니다. 또한, 디지털 병리 도입에는 막대한 인프라 투자, 표준화, 규제 당국의 승인이 필요합니다. 또한, 조직 샘플의 품질 편차, 복잡한 상환 환경, 병원 정보 시스템(HIS/LIS)과의 통합 문제 등이 첨단 병리 기술의 보급에 대한 장벽으로 작용하고 있습니다.
이 보고서는 병리 검사 세계 시장에 대한 종합적인 분석을 제공하는 것을 목표로 합니다. 총 매출액, 주요 기업의 시장 점유율과 순위에 초점을 맞추고, 지역별, 국가별, 유형별, 용도별 병리검사 분석을 포함하고 있습니다.
병리검사 시장의 규모, 추정 및 예측은 2024년을 기준 연도로 하여 2020년에서 2031년까지의 기간의 과거 데이터와 예측 데이터를 포함하는 매출액으로 제시되었습니다. 정량적 분석과 정성적 분석을 통해 독자들이 사업/성장 전략을 수립하고, 시장 경쟁 상황을 평가하고, 현재 시장에서의 위치를 분석하고, 병리검사와 관련된 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 돕습니다.
시장 세분화
기업별
- Quest Diagnostics
- Sonic Healthcare
- Lab Corp
- Unilabs
- SYNLAB International
- BML
- Pathologists Diagnostic
- StageBio
- KingMed Diagnostics Group
- Dian Diagnostics Group
- Adicon Clinical Laboratories Inc.
- Huayin Health
유형별 부문
- 조직병리학
- 세포병리학
- 면역조직화학병리학
- 분자병리학
용도별 부문
- 병원
- 임상 검사실
지역별
- 북미
- 미국
- 캐나다
- 아시아태평양
- 중국
- 일본
- 한국
- 동남아시아
- 인도
- 호주
- 기타 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 네덜란드
- 북유럽 국가
- 기타 유럽
- 라틴아메리카
- 멕시코
- 브라질
- 기타 라틴아메리카
- 중동 및 아프리카
- 튀르키예
- 사우디아라비아
- 아랍에미리트
- 기타 중동 및 아프리카
자주 묻는 질문
The global market for Pathological Examination was estimated to be worth US$ 34133 million in 2024 and is forecast to a readjusted size of US$ 65912 million by 2031 with a CAGR of 10.0% during the forecast period 2025-2031.
Pathological examination is a medical diagnostic process that involves the analysis of tissues, cells, or bodily fluids to determine the nature, cause, and extent of disease. It includes techniques such as histopathology, cytology, immunohistochemistry, and molecular pathology. As the gold standard for diagnosing cancers and many other diseases, pathological examination plays a critical role in clinical decision-making, surgical planning, and prognosis assessment.
The pathological examination market is driven by the increasing global incidence of cancer and other chronic diseases that require tissue-based diagnosis. As healthcare systems shift toward precision medicine, the demand for accurate, early-stage diagnostic tools such as histopathology, cytology, and molecular pathology continues to rise. Technological advancements-such as digital pathology, immunohistochemistry (IHC), and next-generation sequencing (NGS)-have expanded the scope of pathology beyond traditional microscopy, improving workflow efficiency, diagnostic accuracy, and enabling personalized treatment strategies.
Despite strong growth potential, the pathological examination market faces key challenges including a shortage of trained pathologists, especially in developing countries. Manual workflow in traditional pathology can be time-consuming and error-prone, and digital pathology implementation requires significant infrastructure investment, standardization, and regulatory approval. Furthermore, variability in tissue sample quality, complex reimbursement environments, and integration issues with hospital information systems (HIS/LIS) continue to pose barriers to the widespread adoption of advanced pathology technologies.
This report aims to provide a comprehensive presentation of the global market for Pathological Examination, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Pathological Examination by region & country, by Type, and by Application.
The Pathological Examination market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pathological Examination.
Market Segmentation
By Company
- Quest Diagnostics
- Sonic Healthcare
- Lab Corp
- Unilabs
- SYNLAB International
- BML
- Pathologists Diagnostic
- StageBio
- KingMed Diagnostics Group
- Dian Diagnostics Group
- Adicon Clinical Laboratories Inc.
- Huayin Health
Segment by Type
- Histopathology
- Cytopathology
- Immunohistochemical Pathology
- Molecular Pathology
Segment by Application
- Hospital
- Medical Laboratory
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Pathological Examination company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Pathological Examination in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Pathological Examination in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Pathological Examination Product Introduction
- 1.2 Global Pathological Examination Market Size Forecast (2020-2031)
- 1.3 Pathological Examination Market Trends & Drivers
- 1.3.1 Pathological Examination Industry Trends
- 1.3.2 Pathological Examination Market Drivers & Opportunity
- 1.3.3 Pathological Examination Market Challenges
- 1.3.4 Pathological Examination Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Pathological Examination Players Revenue Ranking (2024)
- 2.2 Global Pathological Examination Revenue by Company (2020-2025)
- 2.3 Key Companies Pathological Examination Manufacturing Base Distribution and Headquarters
- 2.4 Key Companies Pathological Examination Product Offered
- 2.5 Key Companies Time to Begin Mass Production of Pathological Examination
- 2.6 Pathological Examination Market Competitive Analysis
- 2.6.1 Pathological Examination Market Concentration Rate (2020-2025)
- 2.6.2 Global 5 and 10 Largest Companies by Pathological Examination Revenue in 2024
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Pathological Examination as of 2024)
- 2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 Histopathology
- 3.1.2 Cytopathology
- 3.1.3 Immunohistochemical Pathology
- 3.1.4 Molecular Pathology
- 3.2 Global Pathological Examination Sales Value by Type
- 3.2.1 Global Pathological Examination Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global Pathological Examination Sales Value, by Type (2020-2031)
- 3.2.3 Global Pathological Examination Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Hospital
- 4.1.2 Medical Laboratory
- 4.2 Global Pathological Examination Sales Value by Application
- 4.2.1 Global Pathological Examination Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global Pathological Examination Sales Value, by Application (2020-2031)
- 4.2.3 Global Pathological Examination Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
- 5.1 Global Pathological Examination Sales Value by Region
- 5.1.1 Global Pathological Examination Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Pathological Examination Sales Value by Region (2020-2025)
- 5.1.3 Global Pathological Examination Sales Value by Region (2026-2031)
- 5.1.4 Global Pathological Examination Sales Value by Region (%), (2020-2031)
- 5.2 North America
- 5.2.1 North America Pathological Examination Sales Value, 2020-2031
- 5.2.2 North America Pathological Examination Sales Value by Country (%), 2024 VS 2031
- 5.3 Europe
- 5.3.1 Europe Pathological Examination Sales Value, 2020-2031
- 5.3.2 Europe Pathological Examination Sales Value by Country (%), 2024 VS 2031
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Pathological Examination Sales Value, 2020-2031
- 5.4.2 Asia Pacific Pathological Examination Sales Value by Region (%), 2024 VS 2031
- 5.5 South America
- 5.5.1 South America Pathological Examination Sales Value, 2020-2031
- 5.5.2 South America Pathological Examination Sales Value by Country (%), 2024 VS 2031
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Pathological Examination Sales Value, 2020-2031
- 5.6.2 Middle East & Africa Pathological Examination Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Pathological Examination Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Pathological Examination Sales Value, 2020-2031
- 6.3 United States
- 6.3.1 United States Pathological Examination Sales Value, 2020-2031
- 6.3.2 United States Pathological Examination Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States Pathological Examination Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Pathological Examination Sales Value, 2020-2031
- 6.4.2 Europe Pathological Examination Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe Pathological Examination Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China Pathological Examination Sales Value, 2020-2031
- 6.5.2 China Pathological Examination Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China Pathological Examination Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Pathological Examination Sales Value, 2020-2031
- 6.6.2 Japan Pathological Examination Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan Pathological Examination Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Pathological Examination Sales Value, 2020-2031
- 6.7.2 South Korea Pathological Examination Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea Pathological Examination Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Pathological Examination Sales Value, 2020-2031
- 6.8.2 Southeast Asia Pathological Examination Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia Pathological Examination Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India Pathological Examination Sales Value, 2020-2031
- 6.9.2 India Pathological Examination Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India Pathological Examination Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 Quest Diagnostics
- 7.1.1 Quest Diagnostics Profile
- 7.1.2 Quest Diagnostics Main Business
- 7.1.3 Quest Diagnostics Pathological Examination Products, Services and Solutions
- 7.1.4 Quest Diagnostics Pathological Examination Revenue (US$ Million) & (2020-2025)
- 7.1.5 Quest Diagnostics Recent Developments
- 7.2 Sonic Healthcare
- 7.2.1 Sonic Healthcare Profile
- 7.2.2 Sonic Healthcare Main Business
- 7.2.3 Sonic Healthcare Pathological Examination Products, Services and Solutions
- 7.2.4 Sonic Healthcare Pathological Examination Revenue (US$ Million) & (2020-2025)
- 7.2.5 Sonic Healthcare Recent Developments
- 7.3 Lab Corp
- 7.3.1 Lab Corp Profile
- 7.3.2 Lab Corp Main Business
- 7.3.3 Lab Corp Pathological Examination Products, Services and Solutions
- 7.3.4 Lab Corp Pathological Examination Revenue (US$ Million) & (2020-2025)
- 7.3.5 Lab Corp Recent Developments
- 7.4 Unilabs
- 7.4.1 Unilabs Profile
- 7.4.2 Unilabs Main Business
- 7.4.3 Unilabs Pathological Examination Products, Services and Solutions
- 7.4.4 Unilabs Pathological Examination Revenue (US$ Million) & (2020-2025)
- 7.4.5 Unilabs Recent Developments
- 7.5 SYNLAB International
- 7.5.1 SYNLAB International Profile
- 7.5.2 SYNLAB International Main Business
- 7.5.3 SYNLAB International Pathological Examination Products, Services and Solutions
- 7.5.4 SYNLAB International Pathological Examination Revenue (US$ Million) & (2020-2025)
- 7.5.5 SYNLAB International Recent Developments
- 7.6 BML
- 7.6.1 BML Profile
- 7.6.2 BML Main Business
- 7.6.3 BML Pathological Examination Products, Services and Solutions
- 7.6.4 BML Pathological Examination Revenue (US$ Million) & (2020-2025)
- 7.6.5 BML Recent Developments
- 7.7 Pathologists Diagnostic
- 7.7.1 Pathologists Diagnostic Profile
- 7.7.2 Pathologists Diagnostic Main Business
- 7.7.3 Pathologists Diagnostic Pathological Examination Products, Services and Solutions
- 7.7.4 Pathologists Diagnostic Pathological Examination Revenue (US$ Million) & (2020-2025)
- 7.7.5 Pathologists Diagnostic Recent Developments
- 7.8 StageBio
- 7.8.1 StageBio Profile
- 7.8.2 StageBio Main Business
- 7.8.3 StageBio Pathological Examination Products, Services and Solutions
- 7.8.4 StageBio Pathological Examination Revenue (US$ Million) & (2020-2025)
- 7.8.5 StageBio Recent Developments
- 7.9 KingMed Diagnostics Group
- 7.9.1 KingMed Diagnostics Group Profile
- 7.9.2 KingMed Diagnostics Group Main Business
- 7.9.3 KingMed Diagnostics Group Pathological Examination Products, Services and Solutions
- 7.9.4 KingMed Diagnostics Group Pathological Examination Revenue (US$ Million) & (2020-2025)
- 7.9.5 KingMed Diagnostics Group Recent Developments
- 7.10 Dian Diagnostics Group
- 7.10.1 Dian Diagnostics Group Profile
- 7.10.2 Dian Diagnostics Group Main Business
- 7.10.3 Dian Diagnostics Group Pathological Examination Products, Services and Solutions
- 7.10.4 Dian Diagnostics Group Pathological Examination Revenue (US$ Million) & (2020-2025)
- 7.10.5 Dian Diagnostics Group Recent Developments
- 7.11 Adicon Clinical Laboratories Inc.
- 7.11.1 Adicon Clinical Laboratories Inc. Profile
- 7.11.2 Adicon Clinical Laboratories Inc. Main Business
- 7.11.3 Adicon Clinical Laboratories Inc. Pathological Examination Products, Services and Solutions
- 7.11.4 Adicon Clinical Laboratories Inc. Pathological Examination Revenue (US$ Million) & (2020-2025)
- 7.11.5 Adicon Clinical Laboratories Inc. Recent Developments
- 7.12 Huayin Health
- 7.12.1 Huayin Health Profile
- 7.12.2 Huayin Health Main Business
- 7.12.3 Huayin Health Pathological Examination Products, Services and Solutions
- 7.12.4 Huayin Health Pathological Examination Revenue (US$ Million) & (2020-2025)
- 7.12.5 Huayin Health Recent Developments
8 Industry Chain Analysis
- 8.1 Pathological Examination Industrial Chain
- 8.2 Pathological Examination Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Pathological Examination Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Pathological Examination Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
(주말 및 공휴일 제외)
